Clinical Trial Update: A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy [Phase 4]

View source ↗

Summary

A Phase 4 compassionate-access protocol evaluated the safety of Xolair (omalizumab) in patients aged 6 years and older with severe allergic asthma not controlle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 4 | Status: COMPLETED